International Council for Harmonisation (ICH)
An organisation that brings together regulatory authorities and pharmaceutical industry from Europe, Japan, and the US to develop harmonised guidelines for drug development and registration. ICH guidelines on stability testing, clinical trials, and safety reporting apply to peptide drug development globally.
Technical Context
ICH brings together regulatory authorities (FDA, EMA, PMDA/Japan, Health Canada, Swissmedic, ANVISA/Brazil, NMPA/China, HSA/Singapore, MFDS/Korea) and pharmaceutical industry associations to develop harmonised guidelines for drug development and registration. ICH guideline categories: Quality (Q1-Q14 — stability, impurities, specifications, analytical validation, pharmaceutical development, GMP, quality risk management, continuous manufacturing), Safety (S1-S12 — carcinogenicity, genotoxicity, toxicokinetics, reproductive toxicity, immunotoxicity, biotechnology-derived products), Efficacy (E1-E20 — clinical trial design, dose-response, ethnic factors, GCP, pharmacovigilance, paediatric), and Multidisciplinary (M1-M14 — MedDRA terminology, CTD format, electronic standards, genomics). For peptide drug development, ICH S6(R1) is particularly important — it provides specific guidance for preclinical safety evaluation of biotechnology-derived pharmaceuticals, acknowledging that standard small molecule toxicology approaches may not be appropriate.